ClinicalTrials.Veeva

Menu

Predictive Values of Serum Adiponectin Levels in Aneurysmal Subarachnoid Hemorrhage.

T

Tang-Du Hospital

Status

Unknown

Conditions

Subarachnoid Hemorrhage, Aneurysmal

Study type

Observational

Funder types

Other

Identifiers

NCT02814162
TDSJWKSAH

Details and patient eligibility

About

The purpose of this study is to evaluate the predictive value of serum adiponectin levels in aneurysmal subarachnoid hemorrhage patients.

Full description

Adiponectin (APN) is an abundant protein hormone derived from adipose tissue. It has been suggested to exert anti-inflammatory, antiatherogenic, and vascular protective. Subarachnoid hemorrhage (SAH) comprises about 5% of all strokes with high mortality and permanent disability rates. Although many patients survive from the initial hemorrhage or rebleeding, they suffered from long-term delayed neurological deficits (DNDs), including stroke, delayed cerebral ischemia, cognitive and neuropsychological abnormalities that seriously impact overall function and quality of life. Ruptured cerebral aneurysms are the most common cause of SAH. There is growing evidence supporting APN act as a predictive factor for SAH. The observational study will focus on the predictive value of serum adiponectin levels in aneurysmal subarachnoid hemorrhage (aSAH).

Enrollment

100 estimated patients

Sex

All

Ages

16 to 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Age>18yrs and age<90yrs
  • It shows subarachnoid hemorrhage (SAH) based on computed tomography (CT) scan on admission
  • Aneurysmal subarachnoid hemorrhage confirmed by computed tomography angiography (CTA), magnetic resonance angiography (MRA) or digital subtraction angiography (DSA)
  • SAH grade is assessed by Hunt & Hess classification
  • Informed consented

Exclusion criteria

  • Traumatic subarachnoid hemorrhage
  • Patients with cerebral herniation or highly possible to occur within 2 days from SAH
  • Length of hospital stay is expected to be less than 5 days
  • Duration from onset to admission is more than 48 hours
  • Disturbance of communication or poor compliance to blood collection, imaging examination and follow-up

Trial contacts and locations

1

Loading...

Central trial contact

Min Li, M.D Ph.D; Yan Qu, M.D Ph.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems